Drawing for IDONTRAX

USPTO serial 79438708

IDONTRAX

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
MORRIS, KRISTINA KLOIBER
Law office
TMO LAW OFFICE 116

What this means

Status 680 means the examining attorney approved your mark for publication in the USPTO Official Gazette. Publication for opposition usually follows within weeks, opening a 30-day window for third parties to oppose. Watch for publication (status 686) and monitor the 30-day opposition window.

Status 680: Status 680 means the examining attorney approved your mark for publication in the USPTO Official Gazette. Publication for opposition usually follows within weeks, opening a 30-day window for third parties to oppose.

Need help with IDONTRAX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Dianne M. Smith-Misemer

Dianne M. Smith-Misemer HOVEY WILLIAMS LLP10801 Mastin St., Suite 1000Overland Park, KS 66210United States

Goods and services

ClassDescriptionStatusFirst use
001Diagnostic preparations and reagents other than for medical or veterinary use; screening agents for in-vitro diagnosis for scientific use; diagnostic reagents other than for medical or veterinary use sold in kit form; diagnostic reagents for in-vitro use other than for medical or veterinary use; reagents for in vitro laboratory uses other than for medical or veterinary use; chemical preparations intended for use in DNA analysis, other than for medical or veterinary use; enzymes, other than for medical or veterinary use, for continuous, homogeneous and isothermal amplification processes for DNA-specific models; chemical genetic identity tests comprised of reagents other than for medical or veterinary use; reagents for nucleic acid amplification other than for medical or veterinary useACTIVE—
005Pharmaceutical products for the prevention and treatment of different kind of cancer; preparations and reagents for diagnosis for medical or veterinary use; diagnostic materials, namely, diagnostic preparations for medical or veterinary use; reagents for medical use; chemical reagents for medical or veterinary use; organic reagents for medical or veterinary use; reagents for analysis for medical use; reagents for diagnostic tests for medical use; reagents for genetic testing for medical use; reagents for in vitro use in laboratories for medical use; in vitro diagnostic preparation for medical use; indicators for medical diagnosis, namely, diagnostic preparations for medical purposes; diagnostic substances for medical use; diagnostic biomarking reagents for medical use; diagnostic test kits for detecting gene mutations implicated in cancers comprising, namely, diagnostic agents, preparations and substances for medical purposes, for testing of bodily fluids for use in disease detection, for detecting gene mutations implicated in cancers; in vitro test kits for detecting genetic defects comprising, namely, diagnostic agents, preparations and substances for medical purposes; chemical preparations intended for use in DNA analysis for medical use; genetic identity tests comprising reagents for medical use; preparations for detecting genetic predispositions for medical use; reagents for nucleic acid amplification for medical use; diagnostic preparations for medical and veterinary useACTIVE—
010Apparatus, tools and instruments for medical diagnosis, namely, diagnostic apparatus for the detection of cancer; DNA and RNA testing apparatus for medical use; genetic testing apparatus for medical use; medical diagnostic for testing DNA samples, namely, quantitative polymerase chain reaction (PCR) instrument for medical use; samplers for medical use, namely, sample preparation devices for medical diagnostic usesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 11, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 22, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 22, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 22, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 18, 2026RFNTREFUSAL PROCESSED BY IB—
Apr 24, 2026RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Apr 24, 2026RFRRREFUSAL PROCESSED BY MPU—
Mar 15, 2026RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Mar 14, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 6, 2026DOCKASSIGNED TO EXAMINER—
Dec 12, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 12, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 11, 2025REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance